Otsuka Pharmaceutical Development & Commercialization, Inc.

This study tested a new drug called SEP-363856 to see if it is safe for people with schizophrenia to take over a long period. About 305 adults aged 18 to 65 with schizophrenia took part for up to 57 weeks. The main goal was to track any side effects or serious health issues that …

This study looked at whether people with schizophrenia could safely switch to a new medication called SEP-363856 from their current antipsychotic drugs. About 100 stable patients took the new drug for 8 weeks. Researchers tracked how many stopped treatment due to side effects or …

This early-stage study tested a new drug called VIS171 in 61 people, first in healthy volunteers and then in patients with autoimmune diseases. The main goal was to check safety and how the body processes the drug. Results will help decide if further testing is warranted.

This study looked at the long-term safety of the drug brexpiprazole in teenagers aged 13 to 17 with schizophrenia. Researchers monitored 295 participants for side effects over time. The goal was to see if the drug is safe enough for ongoing maintenance treatment.

This study tested an experimental drug called JNT-517 in 14 teenagers with phenylketonuria (PKU), a genetic condition that causes harmful buildup of an amino acid. Participants took either the drug or a placebo twice daily for 28 days to check safety and how the body processes it…

This study tested whether adding aripiprazole to lamotrigine helps prevent mood episodes in people with bipolar I disorder who recently had a manic or mixed episode. Over 1,100 adults took part and were followed for up to a year. The main goal was to see if the combination reduce…

This study tested a new medicine called VIS649 in 155 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Participants received either the drug or a placebo, and researchers tracked s…

This study looked at the long-term safety of a once-daily medication called centanafadine for children and teens (ages 4 to 17) with ADHD. About 680 participants took the drug for an extended period, and researchers tracked any side effects. The goal was to see if the medicine is…

This study looked at the safety of a new drug called SEP-363856 for people with schizophrenia who switched from their usual antipsychotic medication. About 75 adults who completed a prior study took the new drug for up to 25 weeks. Researchers tracked side effects to see if the d…

This early-stage study tested the safety of the medication brexpiprazole in 43 teenagers aged 13 to 17 with schizophrenia. Researchers monitored side effects, vital signs, and how the drug moved through the body over 17 days. The goal was to see if the drug is safe enough for lar…

This study tested an experimental drug called AVP-786 in 168 people with traumatic brain injury who had symptoms like aggression, agitation, and irritability. The goal was to see if the drug could safely reduce these challenging behaviors. Participants were randomly assigned to r…

This study tested a new medication called centanafadine in 147 adults with moderate to severe binge eating disorder. Participants took either a low dose, a high dose, or a placebo pill daily for several weeks. The main goal was to see if the drug could reduce the number of days p…

This study tested whether aripiprazole, a medication already used for other conditions, can reduce serious behavioral issues like irritability and aggression in children and teens (ages 6-17) with autistic disorder. 98 participants received either the drug or a placebo for 8 week…

This study tested an experimental drug called EB-1020 SR (centanafadine) in 45 adult men with ADHD. The goal was to see if it safely reduces ADHD symptoms like inattention and hyperactivity. Participants took the drug for 4 weeks, and researchers measured changes using a standard…

This study tested an experimental drug called AVP-786 in 145 adults with schizophrenia who still had troubling symptoms despite taking their usual antipsychotic medication. The goal was to see if adding AVP-786 could reduce negative symptoms like lack of motivation and social wit…

This study tested a once-daily pill called centanafadine in 315 adults with both ADHD and anxiety (generalized or social). Over 8 weeks, researchers measured changes in ADHD and anxiety symptoms using standard rating scales. The goal was to see if the drug could safely reduce sym…

This study tested whether a once-daily medication called centanafadine can reduce ADHD symptoms in children aged 4 to 12. About 574 children took either the drug or a placebo for 6 weeks. Researchers measured changes in ADHD rating scales to see if the drug worked better than pla…

This study tested whether adding SEP-363856 to standard antidepressants helps adults with major depression who didn't get enough relief from prior treatments. About 929 adults aged 18-65 took either the study drug or a placebo for several weeks. The main goal was to see if depres…

This early-stage study tested a new drug called CAN10 in 80 people to see if it is safe and how the body handles it. First, healthy volunteers received a single dose. Then, people with mild to moderate plaque psoriasis received multiple doses. The goal was to check for side effec…

This study tested whether a new drug, SEP-363856, can reduce anxiety symptoms in adults with Generalized Anxiety Disorder. About 434 people aged 18 to 65 took part for up to 12 weeks. Researchers measured anxiety levels using a standard scale to see if the drug worked better than…

This study looked at how centanafadine, a potential ADHD treatment, affects the body when taken with common stimulant drugs like methylphenidate and lisdexamfetamine. Forty healthy adults participated to measure changes in blood pressure, heart rate, and drug levels. The goal was…

This study tested a new once-daily capsule form of the ADHD drug centanafadine in 174 healthy adults. Researchers checked whether different capsule strengths work the same, how food changes drug absorption, and if the new capsule matches the older tablet. The goal was to gather d…

This early-stage study tested a new drug called VIS649 in 51 healthy adults to see if it is safe and how the body processes it. VIS649 is designed to target a protein linked to IgA nephropathy, a kidney disease. The study compared different single doses of the drug against a plac…

This study looked at how a single dose of the experimental drug JNT-517 is absorbed, broken down, and removed from the body. Eight healthy men took the drug, and researchers measured its levels in blood, urine, and stool. The goal was to understand the drug's behavior and safety,…

This study looked at whether a new drug called EB-1020 has the potential to be abused, like other stimulants. Healthy adults who use stimulants recreationally were given single doses of EB-1020, a placebo (sugar pill), or d-amphetamine (a known stimulant) to compare their effects…

This early-stage study tested a new drug called AVP-786 in 56 healthy adult men to see how the body processes it and whether it is safe. Participants took the drug and were monitored for side effects and drug levels in the blood. The study did not aim to treat any disease, but to…

This early-phase study tested the safety and how the body processes AVP-786 in 48 healthy adult men. Participants received single or multiple doses of the drug or a placebo. The goal was to gather information on drug levels and side effects, not to treat any disease.

This study was the first time a new drug called VIS954 was tested in humans. It involved 54 healthy adults to check if the drug is safe and how the body processes it. Participants received either the drug or a placebo, and researchers monitored for side effects and measured drug …

This early-stage study looked at how a new drug called EB-1020 behaves in the body when taken with or without food. It involved 54 healthy adults aged 18-45. The main goals were to check safety, tolerability, and how food changes drug levels in the blood. No treatment was given f…

This study looked at how two different versions of the drug centanafadine are absorbed by the body. 62 healthy adults took either a sustained-release tablet or an extended-release capsule. The goal was to compare the two forms, not to treat any disease.

This study looked at how a new tuberculosis drug, OPC-167832, interacts with other medicines in 24 healthy adults. Participants took the drug alone and with either a common antifungal or seizure medication to see how their bodies processed it. The goal was to check for safety and…

This study gave a single dose of a radioactive-labeled drug (OPC-167832) to 8 healthy men to measure how much leaves the body in urine and stool. The goal was purely to understand the drug's journey, not to treat any disease. Participants stayed in a research unit for the entire …

This early-stage study tested a new oral drug called SEP-380135 in 43 adults with schizophrenia or major depression (including bipolar disorder). The main goal was to check if the drug is safe and how the body processes it. Researchers measured side effects, vital signs, and mood…

This study looked at how a common antifungal drug (itraconazole) changes the amount of two experimental drugs (AVP-923 and AVP-786) in the blood. Twenty-four healthy adults took part to help researchers understand these interactions and check for side effects. The goal was to gat…

This study looked at how a drug called quinidine changes the way the body processes a new schizophrenia medicine, SEP-380135. It involved 12 healthy adults who took a single dose of SEP-380135 with and without quinidine. The goal was to understand potential drug interactions, not…

This study followed over 3,400 people with ADPKD, a genetic condition that causes kidney cysts, to better understand how the disease progresses. Researchers measured kidney size and tracked symptoms, quality of life, and healthcare costs. No treatments were tested; the goal was t…

This early-stage study looked at how two experimental drugs, AVP-786 and AVP-923, are processed by the body. It involved 62 healthy adults aged 18 to 60. The goal was to measure drug levels and check safety, not to treat any disease.

This study looked at whether taking two smaller capsules of the drug centanafadine is equivalent to taking one larger capsule. It involved 44 healthy adults and measured drug levels in the blood. The goal was to confirm dosing options, not to treat any disease.